SPECIAL COMMENTARYNew treatment options for multiresistant gram negativesPaterson, David L.a,b; Isler, Burcua,c; Stewart, Adama,bAuthor Information aUniversity of Queensland Centre for Clinical Research bInfectious Diseases Unit, Royal Brisbane and Women's Hospital, Brisbane, Australia cSisli Etfal Training and Research Hospital, Istanbul, Turkey Correspondence to David L. Paterson, Director, UQ Centre for Clinical Research Faculty of Medicine, The University of Queensland, Level 8, Building 71/918, UQCCR, RBWH Campus, Herston, QLD 4029, Australia. Tel: +61 7 3346 5500; fax: +61 7 3346 5509; e-mail: email@example.com Current Opinion in Infectious Diseases: April 2020 - Volume 33 - Issue 2 - p 214-223 doi: 10.1097/QCO.0000000000000627 Buy Metrics Abstract Purpose of review Multidrug-resistant (MDR) Gram-negative bacteria infections are listed among the top public health threats of the current era. As a result, there has been an increase in efforts to develop new therapeutic agents against MDR Gram-negatives. The purpose of this review is to summarize the clinical and preclinical findings associated with recently approved drugs and the drugs in clinical development against ESBL and carbapenemase-producing Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii infections. Recent findings There are a number of ESBL active agents in late stage clinical development that can help spare carbapenems. Likewise, recently approved β-lactam/β-lactamase inhibitor combinations allow a change in the treatment of KPC and OXA-48 producers and carbapenem-resistant P. aeruginosa from colistin to new, safer agents. Treatment of Meta-beta-lactamase (MBL) producers remains an unmet need – apart from cefiderocol, most agents with MBL activity are still in clinical development. Among the few agents with carbapenem-resistant A. baumannii activity, durlobactam/sulbactam in phase III clinical trials provides hope. Summary Armamentarium against MDR Gram-negatives has expanded with the dominance of agents active against ESBL and KPC producers. There is a need to prioritize MBL producers and carbapenem-resistant A. baumannii, as well as the need for clinical trials to test the new agents against serious infections. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.